Venolife Duo tablets 1000mg, No. 30

Venolife Duo is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Therapy for symptoms of venous lymphatic insufficiency:

- pain;

- cramps of the lower extremities;

- a feeling of heaviness and fullness in the legs;

- 'tiredness' of the legs.

Therapy of manifestations of venous-lymphatic insufficiency:

- edema of the lower extremities;

- trophic changes in the skin and subcutaneous tissue;

- venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Inside.

The recommended dose for venous-lymphatic insufficiency is 1000 mg per day, preferably in the morning, with meals.

The tablets should be swallowed with water.

The risk on the tablet is intended solely for dividing to facilitate swallowing.

The duration of the course of treatment can be several months (up to 12 months).

In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

The recommended dose for acute hemorrhoids is 3000 mg per day (1000 mg in the morning, afternoon and evening) for 4 days, then 2000 mg per day (1000 mg in the morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1000 mg per day.

One film-coated tablet contains:

active substance:

Purified micronized flavonoid fraction (in terms of anhydrous substance) containing diosmin (90%) and other flavonoids (10%) - 1000 mg.

Excipients:

gelatin, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch, talc.

The composition of the film shell :

ready-made mixture for Vivacoat film coating of orange-pink color (macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, iron dye red oxide, iron dye yellow oxide), sodium lauryl sulfate.

Hypersensitivity to active ingredients or to excipients that make up the drug.

It is not recommended to take the drug for lactating women.

Trade name : Venolife Duo

International Non- Proprietary Name: Purified Micronized Flame

wonoid fraction (diosmin + flavonoids in terms of hesperidin)

Dosage form: film-coated tablets

Composition:

One film-coated tablet contains:

active substance:

Purified micronized flavonoid fraction (in terms of anhydrous substance) containing diosmin (90%) and other flavonoids (10%) - 1000 mg.

Excipients:

gelatin, magnesium stearate, microcrystalline cellulose, sodium carboxymethyl starch, talc.

The composition of the film shell :

ready-made mixture for Vivacoat film coating of orange-pink color (macrogol 6000, titanium dioxide, glycerol, magnesium stearate, hypromellose, iron dye red oxide, iron dye yellow oxide), sodium lauryl sulfate.

Description

Dosage 500 mg:

Oval biconvex film-coated tablets, orange-pink in color.

At the fracture, the tablet is from light yellow to gray-yellow in color, inhomogeneous structure. Marbling is allowed.

Dosage 1000 mg:

Oval biconvex film-coated tablets, orange-pink in color with a line on both sides.

At the fracture, the tablet is from light yellow to gray-yellow in color, inhomogeneous structure.

Marbling is allowed.

Pharmacotherapeutic group: Venotonic and venoprotective agent.

Pharmacological properties

Pharmacodynamics

The combination of diosmin + hesperidin has venotonic and angioprotective properties.

The drug reduces the distensibility of veins and venous stasis, reduces capillary permeability and increases their resistance.

The results of clinical studies confirm the pharmacological activity of the drug in relation to the parameters of venous hemodynamics.

A statistically significant dose-dependent effect of the drug was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, venous emptying time.

The optimal dose-response ratio observed when taking 1000 mg per day.

The combination of diosmin + hesperidin increases venous tone: with the help of venous occlusive plethysmography, a decrease in venous emptying time has been shown.

In patients with signs of severe microcirculation disorders, after drug therapy, there was a (statistically significant compared with placebo) increase in capillary resistance, assessed by angiostereometry.

The therapeutic efficacy of the combination of diosmin + hesperidin has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.

Pharmacokinetics

The main excretion of the drug occurs in the feces. With urine, on average, about 14% of the taken amount of the drug is excreted.

The half-life is 11 hours.

The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine.

Indications for use

Venolife Duo is indicated for the treatment of symptoms of chronic venous diseases (elimination and relief of symptoms).

Therapy for symptoms of venous lymphatic insufficiency:

- pain;

- cramps of the lower extremities;

- a feeling of heaviness and fullness in the legs;

- 'tiredness' of the legs.

Therapy of manifestations of venous-lymphatic insufficiency:

- edema of the lower extremities;

- trophic changes in the skin and subcutaneous tissue;

- venous trophic ulcers.

Symptomatic therapy of acute and chronic hemorrhoids.

Contraindications

Hypersensitivity to active ingredients or to excipients that make up the drug.

It is not recommended to take the drug for lactating women.

Application during pregnancy and during breastfeeding

Pregnancy

Animal experiments did not reveal teratogenic effects.

So far, there have been no reports of unwanted effects when using

drug for pregnant women.

Lactation

Due to the lack of data on the elimination of the drug in breast milk, lactating women are not recommended to take the drug.

Impact on reproductive function

Reproductive toxicity studies have shown no effect on reproductive function in rats of either sex.

Method of administration and dosage

Inside.

The recommended dose for venous-lymphatic insufficiency is 1000 mg per day, preferably in the morning, with meals.

The tablets should be swallowed with water.

The risk on the tablet is intended solely for dividing to facilitate swallowing.

The duration of the course of treatment can be several months (up to 12 months).

In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

The recommended dose for acute hemorrhoids is 3000 mg per day (1000 mg in the morning, afternoon and evening) for 4 days, then 2000 mg per day (1000 mg in the morning and evening) for the next 3 days.

The recommended dose for chronic hemorrhoids is 1000 mg per day.

Side effect

Side effects of the combination of diosmin + hesperidin observed during clinical

studies were mild.

Disorders from the gastrointestinal tract were mainly noted (diarrhea, dyspepsia, nausea, vomiting).

During the reception of the combination of diosmin + hesperidin, the following side effects were reported

effects, in the form of the following gradation: very often (? 1/10); often (? 1/100, <1/10); infrequently

(? 1/1000, <1/100); rarely (? 1/10 000, <1/1 000); extremely rare (<1/10 000), unspecified frequency (frequency cannot be estimated from available data).

From the side of the central nervous system:

Rarely: dizziness, headache, general malaise.

From the gastrointestinal tract:

Often: diarrhea, indigestion, nausea, vomiting.

Uncommon: colitis.

Frequency not specified: abdominal pain.

From the side of the skin:

Rare: rash, itching, urticaria.

Unspecified frequency: isolated edema of the face, lips, eyelids. In exceptional cases

angioedema.

Inform the doctor about the appearance of any, including those not mentioned in this

instructions for undesirable reactions, as well as changes in laboratory parameters during therapy.

Overdose

Overdose cases have not been described.

In case of drug overdose, seek medical attention immediately.

Interaction with other medicinal products

Clinical studies to study the interactions of the combination of diosmin + hesperidin

with other drugs has not been carried out.

To date, no identified cases of drug interactions have been reported.

special instructions

- Before you start taking Venolife Duo, it is recommended to consult your doctor.

- In case of exacerbation of hemorrhoids, the appointment of Venolife Duo does not replace the specific treatment of other anal disorders.

The duration of treatment should not exceed the time specified in the section 'Dosage and Administration'.

In the event that the symptoms do not disappear after the recommended course of therapy, you should be examined by a proctologist, who will select further therapy.

- In the presence of disorders of venous circulation, the maximum effect of treatment is provided by a combination of therapy with a healthy (balanced) lifestyle: it is advisable to avoid long exposure to the sun, prolonged stay on the legs, and also, it is recommended to reduce excess body weight.

Hiking and, in some cases, wearing special stockings can improve blood circulation.

See your doctor immediately if your condition worsened during treatment

or there is no improvement.

Influence on the ability to drive vehicles, mechanisms

There have been no clinical studies examining the effect of the combination of diosmin + hesperidin on the ability to drive and perform work that requires a high speed of mental and physical reactions.

However, based on the available safety data, it can be concluded that diosmin + hesperidin does not affect (do not have a significant effect) on these processes.

Release form

500 mg or 1000 mg tablets.

10 or 15 tablets in a blister strip packaging.

3 or 6 blisters of 10 tablets, or 2 or 4 blisters

packs of 15 tablets, together with instructions for use, are placed in a carton box.

Storage conditions

At a temperature not higher than 25 ? C.

Keep out of the reach of children.

Shelf life

2 years

Do not use after the expiration date.

Vacation conditions

Available without a prescription.